Impact of Pharmacist Counselling on Clozapine Knowledge.
Loading...
Authors
Ní Dhubhlaing, Ciara
Young, Ailish
Sahm, Laura J
Issue Date
2017-06-13
Type
Journal Article
Language
en
Keywords
Alternative Title
Abstract
Clozapine is the only antipsychotic with evidence for efficacy in treatment of resistant schizophrenia but it carries a high side effect burden. Patient information is provided but may be poorly retained. This study aims to examine the impact of pharmacist counselling upon patient knowledge of clozapine. Outpatients, aged 18 years and over, attending St. Patrick's University Hospital, Dublin, participated in this study between June and August 2015. The intervention consisted of pharmacist counselling on two occasions one month apart. Knowledge was assessed using a 28-point checklist devised from the currently available clozapine patient information sources, at baseline and after each counselling session. Ethics approval was obtained. Twenty-five participants (40% female; mean age 45.1 years, SD 9.82; 64% unemployed, 28% smokers) showed an improvement in knowledge scores of clozapine from baseline to postcounselling on each occasion with an overall improvement in knowledge score, from baseline to postcounselling at one month, of 39.43%; < 0.001. This study adds to the evidence that interventions involving pharmacist counselling can improve patient knowledge, whilst the specific knowledge gained relating to recognition of side effects may help patients towards more empowerment regarding their treatment.
Description
Citation
Ní Dhubhlaing, C., Young, A., & Sahm, L. J. (2017). Impact of Pharmacist Counselling on Clozapine Knowledge. Schizophrenia research and treatment, 2017, 6120970. https://doi.org/10.1155/2017/6120970
Publisher
License
Journal
Schizophrenia research and treatment
Volume
2017
Issue
PubMed ID
DOI
10.1155/2017/6120970
10.1007/s40263-017-0411-6
10.1016/j.pec.2010.10.032
10.1080/09540120903431355
10.1192/bjp.168.6.709
10.3390/pharmacy2010114
10.1177/1757913911431038
10.1111/j.1525-1497.2003.10651.x
10.1192/pb.19.9.536
10.1001/archpsyc.60.6.565
10.1192/bjp.bp.111.105833
10.1080/10810730.2012.718041
10.1016/j.schres.2005.02.010
10.1177/1715163513500208
10.4103/0971-6580.94506
10.1016/0006-3223(93)90043-D
10.1007/s40263-017-0411-6
10.1016/j.pec.2010.10.032
10.1080/09540120903431355
10.1192/bjp.168.6.709
10.3390/pharmacy2010114
10.1177/1757913911431038
10.1111/j.1525-1497.2003.10651.x
10.1192/pb.19.9.536
10.1001/archpsyc.60.6.565
10.1192/bjp.bp.111.105833
10.1080/10810730.2012.718041
10.1016/j.schres.2005.02.010
10.1177/1715163513500208
10.4103/0971-6580.94506
10.1016/0006-3223(93)90043-D
ISSN
2090-2085